Candel Therapeutics(CADL.US)

Last Updated 19:00:00 ET
longbridge loading

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

benzinga_article·
US
CADL
+3.92%
US
LABU
+9.05%
US
SBIO
+2.85%
benzinga_article·
US
CADL
+3.92%
US
LABU
+9.05%
US
SBIO
+2.85%

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

Tip Ranks·
US
CADL
+3.92%
US
SBIO
+2.85%
US
XBI
+3.00%
Tip Ranks·
US
CADL
+3.92%
US
SBIO
+2.85%
US
XBI
+3.00%

Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
+3.92%
Earnings Watch·
US
CADL
+3.92%

Candel Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
+3.92%
Earnings Watch·
US
CADL
+3.92%

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | CADL Stock News

StockTitan·
US
CADL
+3.92%
US
BIB
+3.43%
US
PBE
+0.89%
StockTitan·
US
CADL
+3.92%
US
BIB
+3.43%
US
PBE
+0.89%
© 2026 Longbridge｜Disclaimer